Gerald Reischl

Otfried Mueller Str. 14
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications

The PET tracer [11C]MODAG-005 targets alpha-synuclein aggregates in the brain.

The PET tracer [11C]MODAG-005 targets alpha-synuclein aggregates in the brain.

Journal: Science translational medicine
Published: May 27, 2026

Correlation of [18F]SiTATE-PET-tracer with somatostatin receptor expression in meningiomas: an exploratory ex vivo histological pilot study.

Correlation of [18F]SiTATE-PET-tracer with somatostatin receptor expression in meningiomas: an exploratory ex vivo histological pilot study.

Journal: EJNMMI research
Published: February 17, 2026

The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management.

The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management.

Journal: European journal of nuclear medicine and molecular imaging
Published: June 30, 2025

Noninvasive Monitoring of Inflammatory Processes by Myeloid Cell-Directed PET Tracers in an Experimental Severe Acute Respiratory Syndrome Coronavirus 2 Infection Model.

Noninvasive Monitoring of Inflammatory Processes by Myeloid Cell-Directed PET Tracers in an Experimental Severe Acute Respiratory Syndrome Coronavirus 2 Infection Model.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 14, 2025

Histologic Ex Vivo Validation of the [18F]SITATE Somatostatin Receptor PET Tracer.

Histologic Ex Vivo Validation of the [18F]SITATE Somatostatin Receptor PET Tracer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 31, 2025

Functional PET/MRI reveals active inhibition of neuronal activity during optogenetic activation of the nigrostriatal pathway.

Functional PET/MRI reveals active inhibition of neuronal activity during optogenetic activation of the nigrostriatal pathway.

Journal: Science advances
Published: October 25, 2024

PSMA-Guided Imaging and Therapy of Advanced Adenoid Cystic Carcinomas and Other Salivary Gland Carcinomas.

PSMA-Guided Imaging and Therapy of Advanced Adenoid Cystic Carcinomas and Other Salivary Gland Carcinomas.

Journal: Cancers
Published: October 25, 2024

One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging.

One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging.

Journal: European journal of nuclear medicine and molecular imaging
Published: September 13, 2024

Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up.

Focal Unspecific Bone Uptake on [18F]PSMA-1007 PET: Evaluation Analog PROMISE Criteria and Validation via PET/CT Follow-Up.

Journal: Diagnostics (Basel, Switzerland)
Published: August 16, 2024

Low-activity [18F]-somatostatin receptor (SSTR) imaging using [18F]SiTATE on a long axial field-of-view PET/CT scanner.

Low-activity [18F]-somatostatin receptor (SSTR) imaging using [18F]SiTATE on a long axial field-of-view PET/CT scanner.

Journal: EJNMMI physics
Published: May 20, 2024

CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients.

CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients.

Journal: Biomarker research
Published: February 08, 2024

Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.

Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.

Journal: Clinical nuclear medicine
Published: January 25, 2024
Showing 1-12 of 84

Last Updated: 09/26/2026